Medications · Metabolic & weight

Topiramate

Anticonvulsant used off-label in metabolic contexts.

Why this needs to be personal

Why Personalized Topiramate

Topamax was approved on doses that worked acceptably across the average of seizure and migraine trials. The commercial tablet strengths are 25, 50, 100, and 200 mg, with the migraine target landing at 100 mg/day. Those numbers were not picked for your tolerance of the word-finding difficulty that gives topiramate its nickname, your history of kidney stones, your bicarbonate baseline, your weight, or the dose at which paresthesias become disruptive. Topiramate is one of the clearest cases where the side effects, cognitive slowing, tingling, stone risk, are dose-dependent, and the dose that finally controls migraines for one patient is the dose that another patient cannot work through.

That is the work a compounding pharmacy does. A prescriber can start at 12.5 mg instead of 25, hold at 18.75 mg for a week before stepping to 25, or settle a patient at 37.5 or 75 mg if that is where benefit and tolerability meet. None of those strengths exist on a manufactured tablet. The molecule is the same one the FDA reviewed in 1996. A pediatric patient who needs a precise weight-based dose, or an adult who reacts to a tablet excipient, can be prepared an allergen-free oral suspension or a custom-strength capsule for that single prescription.

This is what pharmacy looked like before mass manufacturing arrived. A doctor wrote the prescription. A pharmacist prepared it for that patient. Compounded topiramate is that older arrangement, kept honest by modern oversight.

In brief

Topiramate Explained

Topiramate is an oral anticonvulsant that has been FDA-approved since 1996 for epilepsy and since 2004 for migraine prevention ⁹²⁴. The brand name is Topamax, and generic topiramate has been available for many years ³². A combination capsule of phentermine and topiramate, Qsymia, was approved in 2012 for chronic weight management ³³¹⁹.

Doctors also use topiramate off-label for alcohol use disorder, binge eating disorder, idiopathic intracranial hypertension, essential tremor, and post-traumatic stress disorder. Common side effects include tingling in the hands and feet (paresthesias), trouble finding words, fatigue, and weight loss. Topiramate can cause kidney stones, lower the body's bicarbonate (metabolic acidosis), and reduce sweating in children. Taken in early pregnancy it raises the risk of cleft lip and cleft palate ³⁰.

For clinicians

Topiramate is an oral sulfamate-substituted monosaccharide with broad-spectrum anticonvulsant activity. It was FDA-approved in 1996 (Topamax) as adjunctive therapy for partial-onset and primary generalized tonic-clonic seizures in adults ¹, with subsequent approvals for monotherapy in patients with epilepsy ², for Lennox-Gastaut syndrome adjunctive therapy ⁴, for migraine prophylaxis in adults (2004) ⁹¹⁰, and as the phentermine/topiramate fixed-dose combination Qsymia for chronic weight management (2012) ¹⁹²¹²⁵ ³²³³. Mechanism is multimodal: state-dependent sodium-channel blockade, potentiation of GABA-A receptor activity at a non-benzodiazepine site, antagonism at AMPA/kainate glutamate receptors, and inhibition of carbonic anhydrase isoforms II and IV ⁵.

Phase III evidence supports adjunctive epilepsy use ¹, monotherapy ², Lennox-Gastaut ⁴, migraine prophylaxis at 100 mg/day (MIGR-001 ¹⁰ and MIGR-002 ⁹), pediatric migraine where the CHAMP trial demonstrated no separation from placebo for amitriptyline or topiramate ²⁸, and obesity at lower doses combined with phentermine in CONQUER ¹⁹, EQUIP ²¹, and the two-year SEQUEL extension ²⁵. Well-studied off-label evidence supports topiramate for alcohol use disorder ⁸, binge eating disorder associated with obesity ¹³, idiopathic intracranial hypertension ¹⁶, civilian PTSD ²⁰, and essential tremor ¹²¹⁸ ¹⁷. Cochrane reviews integrate the migraine prophylaxis ²⁶ and bipolar acute affective episode ²⁷ literatures.

Safety is dominated by neurocognitive effects (word-finding difficulty, psychomotor slowing, paresthesias) ²³¹⁴, metabolic acidosis from carbonic anhydrase inhibition, nephrolithiasis ²⁹⁶, oligohidrosis in pediatric patients ³¹, and a documented teratogenic signal for oral clefts in first-trimester exposure ²⁴²²³⁰. Topiramate at doses ≥200 mg/day reduces ethinyl estradiol AUC by approximately 20-30%, with implications for combined oral contraceptive efficacy ³⁷. Generic topiramate is widely available; the compounded 503A role is narrow ³².

At a glance

Quick Facts About Topiramate

Category: Sulfamate-substituted monosaccharide anticonvulsant
Active ingredient: Topiramate, a structurally distinct anticonvulsant derived from D-fructose with multiple molecular targets (sodium channels, GABA-A potentiation, AMPA/kainate antagonism, carbonic anhydrase inhibition)
FDA-approved branded forms: Topamax (immediate-release; epilepsy 1996, migraine prophylaxis 2004); Trokendi XR and Qudexy XR (extended-release); Qsymia (phentermine/topiramate ER combination for chronic weight management, 2012)
Routes: Oral (tablets, sprinkle capsules, extended-release capsules); compounded preparations may include suspensions and other patient-specific oral forms
Evidence posture: Multiple pivotal phase III trials support epilepsy adjunctive and monotherapy use, migraine prophylaxis, and the phentermine/topiramate combination for obesity; well-studied off-label evidence exists for alcohol use disorder and binge eating disorder
FDA-approval status: Manufactured Topamax (and generics), Trokendi XR, Qudexy XR, and Qsymia are FDA-approved. Compounded topiramate preparations are not FDA-approved.
Compounded under: 503A, patient-specific prescription only, where the manufactured FDA-approved product is not clinically appropriate (e.g., excipient sensitivity, pediatric custom strength, allergen-free oral suspension)
Pregnancy / contraception cautions: Former FDA pregnancy Category D. Topiramate exposure in the first trimester is associated with an increased risk of oral clefts. Topiramate also reduces ethinyl estradiol exposure, particularly at higher doses, which can lower combined oral contraceptive efficacy.

Prescription review

Patient-Specific Prescription Only

Topiramate on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.

Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
Named-patient label. The bottle carries your name. The batch records carry your prescription.
Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.

For prescribing doctors Offer this medication → For patients Find a partner clinic →

Real medicine, not gray market

How This Differs from a Research-Use-Only Website

A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.

A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.

What it is

What is Topiramate?

Topiramate is a structurally distinct anticonvulsant, a sulfamate-substituted monosaccharide derived from D-fructose ³². It was discovered at the R.W. Johnson Pharmaceutical Research Institute in the late 1980s as part of a program originally aimed at developing fructose-1,6-diphosphatase inhibitors, and was repositioned as an antiepileptic following positive results in animal seizure models. The compound's chemistry is unrelated to that of the major established anticonvulsant classes, and its multi-target pharmacology contributes to its broad clinical spectrum ⁵.

Topiramate received its first FDA approval in 1996 as adjunctive therapy for partial-onset seizures in adults under the brand Topamax. The migraine prophylaxis indication followed in 2004 ⁹¹⁰. Extended-release oral formulations (Trokendi XR, Qudexy XR) became available in the 2010s, and a fixed-dose combination of phentermine and topiramate extended-release (Qsymia) was approved in 2012 for chronic weight management in adults with obesity ¹⁹²¹ ³³.

Generic immediate-release topiramate is widely available as oral tablets (25, 50, 100, 200 mg) and sprinkle capsules (15, 25 mg) ³². Extended-release capsules are available at 25, 50, 100, 150, and 200 mg strengths. Qsymia is supplied as fixed-dose phentermine/topiramate ER capsules at 3.75/23, 7.5/46, 11.25/69, and 15/92 mg ³³.

How it works

How Topiramate Works

Class: Anticonvulsant
First studied: 1996 FDA approval
Common forms: Compounded capsule
Compounding category: 503A, patient-specific prescription

Topiramate has multiple molecular targets that together account for its broad-spectrum anticonvulsant activity and its effects in migraine, weight regulation, and other indications. The principal actions characterized in preclinical work include state-dependent blockade of voltage-gated sodium channels, positive allosteric modulation of GABA-A receptors at a non-benzodiazepine binding site, antagonism at AMPA and kainate ionotropic glutamate receptors, blockade of L-type voltage-gated calcium channels, and inhibition of carbonic anhydrase isoforms II and IV ⁵.

Different molecular targets are thought to dominate in different clinical contexts. The anticonvulsant effect is attributed primarily to sodium-channel modulation, GABA-A potentiation, and AMPA/kainate antagonism. The migraine prophylactic effect is hypothesized to involve cortical excitability dampening through similar channel-level mechanisms plus inhibition of trigeminovascular activation. The weight-loss effect, leveraged in the Qsymia combination, is attributed to appetite suppression and changes in food preference that may involve GABA-A and AMPA modulation in hypothalamic and reward circuits. Carbonic anhydrase inhibition contributes to metabolic acidosis, paresthesias, nephrolithiasis, and oligohidrosis observed as adverse effects ⁵²⁹⁶.

Research history

Topiramate Research History

Topiramate was synthesized at the R.W. Johnson Pharmaceutical Research Institute in the 1980s. The pivotal adjunctive epilepsy program in adults with refractory partial-onset seizures was reported by Faught and colleagues (the YD Study Group) in Neurology in 1996, demonstrating dose-dependent seizure reduction at 200, 400, and 600 mg/day ¹. Monotherapy and additional adjunctive evidence in epilepsy followed from Sachdeo and colleagues for partial-onset seizures ² and for Lennox-Gastaut syndrome (YL Study Group) ⁴. The Shank et al. 2000 Epilepsia review consolidated the preclinical pharmacology and PK rationale that supported the broad-spectrum clinical profile ⁵.

Migraine prophylaxis was established through two parallel pivotal trials reported in 2004: MIGR-001 ¹⁰ in Archives of Neurology and MIGR-002 ⁹ in JAMA, with 100 mg/day emerging as the optimum dose for migraine frequency reduction with acceptable tolerability. The 2013 Cochrane review by Linde et al. integrated topiramate and other agents for episodic migraine prophylaxis ²⁶. The CHAMP trial reported by Powers and colleagues in NEJM in 2017 tested amitriptyline and topiramate against placebo in pediatric migraine, with neither active arm separating from placebo ²⁸, a result that tempered enthusiasm for prophylactic pharmacotherapy in children with migraine.

The obesity program leveraged topiramate's appetite-suppressant effect, first reported by Wilding et al. in a long-term double-blind monotherapy trial in obese adults at doses up to 384 mg/day ¹¹. Topiramate monotherapy at high doses was poorly tolerated, motivating the lower-dose combination with phentermine. The phase III program for the fixed-dose phentermine/topiramate ER combination produced EQUIP (severely obese adults, Allison 2012 ²¹), CONQUER (overweight and obese adults with comorbidities, Gadde 2011 ¹⁹), and the SEQUEL two-year extension ²⁵, leading to FDA approval as Qsymia in July 2012.

Off-label indications developed largely in academic clinical trials. Johnson and colleagues established efficacy for alcohol dependence in a Lancet RCT in 2003 ⁸ and a JAMA RCT in 2007 ¹⁷. McElroy et al. reported a placebo-controlled trial for binge eating disorder associated with obesity in Biological Psychiatry in 2007 ¹³. Çelebisoy et al. compared topiramate with acetazolamide in idiopathic intracranial hypertension ¹⁶. Connor et al. and Ondo et al. demonstrated efficacy in essential tremor in placebo-controlled crossover and parallel-group trials ¹⁸¹². Yeh et al. reported a positive RCT for civilian PTSD in 2011 ²⁰. Vasudev et al. summarized the bipolar acute affective episode literature in a 2016 Cochrane review with predominantly null findings ²⁷.

The teratogenicity signal emerged from pregnancy registry analyses. Margulis et al. reported an increased risk of oral clefts in 2012 ²⁴, consistent with the Hernandez-Diaz comparative AED safety analysis in Neurology in 2012 ²² and confirmed in a larger pregnancy cohort study in Neurology in 2018 ³⁰. The Doose et al. oral contraceptive PK studies in 1997 and 2003 ³⁷ established the dose-dependent reduction in ethinyl estradiol AUC that informs contraceptive counseling for women of reproductive age on topiramate. Pediatric ASM safety surveillance ³¹ catalogues oligohidrosis and other carbonic-anhydrase-related effects that warrant particular vigilance in children.

Timeline

Topiramate Timeline

1996 Faught et al ¹. publish dose-ranging placebo-controlled trial of topiramate 200, 400, and 600 mg/day in refractory partial epilepsy (YD Study Group, Neurology)
1996 FDA approves Topamax as adjunctive therapy for partial-onset seizures in adults ³²
1997 Sachdeo et al ². publish topiramate monotherapy in partial-onset seizures (Epilepsia)
1997 Doose et al ³. characterize the effect of topiramate on the PK of an oral contraceptive containing norethindrone and ethinyl estradiol in adults with epilepsy (Epilepsia)
1999 Sachdeo et al ⁴. publish double-blind randomized trial of topiramate in Lennox-Gastaut syndrome (YL Study Group, Neurology)
2000 Shank et al ⁵. publish overview of preclinical topiramate pharmacology, PK, and mechanism (Epilepsia)
2002 Kossoff et al ⁶. describe kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet, establishing nephrolithiasis as a class effect of carbonic-anhydrase-inhibiting anticonvulsants (Epilepsia)
2003 Johnson et al ⁸. publish oral topiramate for treatment of alcohol dependence (Lancet RCT)
2003 Doose et al ⁷. extend the oral contraceptive PK characterization to obese and nonobese healthy female subjects on topiramate vs carbamazepine (Epilepsia)
2004 Brandes et al. (MIGR-002, JAMA) and Silberstein et al ⁹¹⁰³². (MIGR-001, Archives of Neurology) publish pivotal migraine prophylaxis trials, FDA approves Topamax for migraine prophylaxis in adults
2004 Wilding et al ¹¹. publish long-term double-blind placebo-controlled study of topiramate monotherapy in obese adults (Int J Obes Relat Metab Disord)
2006 Ondo et al ¹². publish double-blind placebo-controlled trial of topiramate in essential tremor (Neurology)
2007 McElroy et al ¹³. publish placebo-controlled trial of topiramate for binge eating disorder associated with obesity (Biological Psychiatry)
2007 Salinsky et al ¹⁴. characterize topiramate's EEG and alertness effects in healthy volunteers (Epilepsy & Behavior)
2007 Diener et al ¹⁵. publish RCT of topiramate in chronic migraine (Cephalalgia)
2007 Çelebisoy et al ¹⁶. compare topiramate with acetazolamide in idiopathic intracranial hypertension (Acta Neurologica Scandinavica)
2007 Johnson et al ¹⁷. publish second pivotal RCT of topiramate for alcohol dependence (JAMA)
2008 Connor et al ¹⁸. publish double-blind placebo-controlled crossover trials of topiramate in essential tremor (Clinical Neuropharmacology)
2011 Gadde et al ¹⁹. publish CONQUER, phentermine/topiramate combination for weight and associated comorbidities in overweight and obese adults (Lancet)
2011 Yeh et al ²⁰. publish a double-blind RCT of topiramate in civilian PTSD (CNS Neuroscience & Therapeutics)
2012 Allison et al ²¹. publish EQUIP, controlled-release phentermine/topiramate in severely obese adults (Obesity)
2012 FDA approves Qsymia (phentermine/topiramate ER) for chronic weight management in adults (July 2012) ³³
2012 Garvey et al ²⁵. publish SEQUEL, two-year sustained weight loss and metabolic benefits with phentermine/topiramate ER (Am J Clin Nutr)
2012 Margulis et al. publish topiramate pregnancy oral cleft analysis (Am J Obstet Gynecol) and Hernandez-Diaz et al ²⁴²². report comparative AED safety during pregnancy (Neurology)
2012 Loring et al ²³. characterize the relationship between topiramate plasma concentration and linguistic behavior, verbal recall, and working memory (Epilepsy & Behavior)
2013 Linde et al ²⁶. publish Cochrane review of topiramate for prophylaxis of episodic migraine in adults
2016 Vasudev et al ²⁷. publish Cochrane review of topiramate for acute affective episodes in bipolar disorder, predominantly null findings
2017 Powers et al ²⁸. (CHAMP trial, NEJM) report that neither amitriptyline nor topiramate separated from placebo for pediatric migraine prophylaxis
2018 Hernandez-Diaz et al ³⁰. confirm increased oral cleft risk with first-trimester topiramate exposure in a large pregnancy cohort study (Neurology)
2018 Daudon et al ²⁹. review drug-induced kidney stones and crystalline nephropathy with detailed coverage of topiramate-associated calcium phosphate stones (Drugs)
2021 Franco et al ³¹. analyze pediatric adverse reactions to antiseizure medications, including topiramate-associated oligohidrosis and cognitive effects, in the Italian spontaneous reporting system 2001-2019 (Epilepsy & Behavior)

Natural role

Biological Role of Topiramate

Topiramate has no native biological role, it is a synthetic small molecule with no endogenous counterpart. Its targets are well-characterized components of normal neuronal excitability (voltage-gated sodium and calcium channels, GABA-A receptors, AMPA/kainate glutamate receptors) and of acid-base/ion physiology (carbonic anhydrase isoforms). The therapeutic effect comes from chronic, partial modulation of these systems rather than complete inhibition.

The therapeutic landscape topiramate occupies, broad-spectrum anticonvulsant with secondary indications in migraine, obesity, and substance use disorders, reflects its multi-target pharmacology rather than action on a single disease-specific pathway ⁵. This profile contrasts with newer single-target agents (e.g., GLP-1 receptor agonists for obesity, CGRP-pathway antibodies for migraine) and explains both topiramate's clinical versatility and its broad adverse-effect profile.

Clinical contexts studied

Clinical Contexts for Topiramate

Adjunctive therapy for partial-onset and primary generalized tonic-clonic seizures in adults and pediatric patients ≥2 years fda approved

FDA-approved indication for Topamax (immediate-release) and Trokendi XR / Qudexy XR (extended-release).

Pivotal dose-ranging trials demonstrated dose-dependent seizure reduction at 200, 400, and 600 mg/day in adults with refractory partial-onset seizures ¹. Adjunctive use in Lennox-Gastaut syndrome was supported by the YL Study Group ⁴. Pediatric efficacy data extended labeling to ≥2 years for partial-onset and primary generalized tonic-clonic seizures and ≥2 years adjunctive for Lennox-Gastaut ³².

Branded product: Topamax (topiramate; Janssen) and generics; Trokendi XR (Supernus); Qudexy XR (Upsher-Smith)

Monotherapy for partial-onset or primary generalized tonic-clonic seizures in patients ≥2 years fda approved

FDA-approved indication for Topamax monotherapy.

Monotherapy efficacy was supported by Sachdeo et al. in partial-onset seizures ². Labeling supports topiramate monotherapy in adults and pediatric patients ≥2 years ³².

Branded product: Topamax

Migraine prophylaxis in adults fda approved

FDA-approved indication for Topamax (immediate-release) and Trokendi XR / Qudexy XR (extended-release).

MIGR-001 ¹⁰ and MIGR-002 ⁹ established 100 mg/day as the optimum prophylactic dose for adults with episodic migraine, with significant reductions in mean monthly migraine days vs placebo. The Linde 2013 Cochrane review consolidated topiramate within the migraine prophylaxis evidence base ²⁶ ³². Diener et al. extended the evidence into chronic migraine ¹⁵.

Branded product: Topamax

Chronic weight management in adults with obesity (phentermine/topiramate ER combination) fda approved

FDA-approved indication for Qsymia (phentermine/topiramate ER combination, July 2012).

EQUIP ²¹ demonstrated mean weight reductions of 5.1% and 10.9% with low-dose and full-dose phentermine/topiramate ER vs 1.6% with placebo in adults with severe obesity (BMI ≥35) at 56 weeks ³³. CONQUER ¹⁹ demonstrated mean weight reductions of 7.8% and 9.8% with mid-dose and full-dose vs 1.2% placebo in overweight and obese adults with weight-related comorbidities at 56 weeks. The SEQUEL two-year extension ²⁵ confirmed sustained weight loss and metabolic benefits at 108 weeks. Qsymia is contraindicated in pregnancy (REMS) and requires monthly pregnancy testing in women of reproductive potential.

Branded product: Qsymia (phentermine/topiramate ER; Vivus)

Alcohol use disorder well studied

Off-label; well-studied with two pivotal RCTs.

Johnson et al. 2003 ⁸ randomized 150 adults with alcohol dependence to topiramate (titrated to 300 mg/day) vs placebo for 12 weeks and reported significant reductions in drinks per day, drinks per drinking day, percent days heavy drinking, and gamma-glutamyltransferase. Johnson et al. 2007 ¹⁷ replicated and extended the finding in a larger 14-week multi-site RCT (N=371). Both studies established topiramate as an evidence-supported option for alcohol use disorder, though it remains off-label in the United States.

Binge eating disorder associated with obesity well studied

Off-label; supported by a placebo-controlled RCT.

McElroy et al. 2007 ¹³ randomized adults with binge eating disorder and obesity to topiramate (mean dose ~212 mg/day) vs placebo for 21 weeks and reported significant reductions in binge episode frequency, BMI, and Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating score. Topiramate has not received FDA approval for this indication.

Idiopathic intracranial hypertension well studied

Off-label; supported by a comparator-controlled trial vs acetazolamide.

Çelebisoy et al. 2007 ¹⁶ conducted an open-label comparison of topiramate vs acetazolamide in adults with idiopathic intracranial hypertension and reported comparable improvements in visual field and headache outcomes. Topiramate's carbonic anhydrase inhibition is the proposed mechanistic basis for benefit in this condition.

Essential tremor well studied

Off-label; supported by placebo-controlled trials.

Ondo et al. 2006 ¹² reported a positive double-blind placebo-controlled trial of topiramate (titrated to 400 mg/day) in adults with essential tremor, with significant reduction in Fahn-Tolosa-Marin tremor rating scale. Connor et al. 2008 ¹⁸ reported corroborating evidence in pooled double-blind placebo-controlled crossover trials. Discontinuation rates due to adverse events were high, reflecting the neurocognitive tolerability profile of higher topiramate doses.

Post-traumatic stress disorder well studied

Off-label; supported by a positive RCT in civilian PTSD.

Yeh et al. 2011 ²⁰ conducted a double-blind RCT of topiramate (titrated to 200 mg/day) vs placebo in civilian PTSD over 12 weeks and reported improvements on the Clinician-Administered PTSD Scale. The trial was a single-site study with modest sample size; topiramate has not received FDA approval for PTSD.

Chronic migraine well studied

Off-label for chronic migraine (>15 headache days per month); supported by a placebo-controlled RCT.

Diener et al. 2007 ¹⁵ randomized adults with chronic migraine to topiramate 100 mg/day vs placebo for 16 weeks and reported significant reductions in monthly headache days. Topiramate is FDA-approved for migraine prophylaxis in adults but the labeled indication is for episodic migraine; chronic migraine use is supported by trial evidence but is off-label.

Off-label use

Off-Label Uses of Topiramate

Pediatric migraine prophylaxis well studied

CHAMP trial demonstrated no separation from placebo; evidence does not support routine use in pediatric migraine.

Powers et al. 2017 ²⁸ randomized 361 children and adolescents with migraine to amitriptyline, topiramate, or placebo over 24 weeks (CHAMP trial, NEJM). Neither active arm separated from placebo on the primary endpoint of ≥50% reduction in headache days. The trial tempered enthusiasm for routine prophylactic pharmacotherapy in pediatric migraine.

Acute affective episodes in bipolar disorder well studied

Cochrane review reports predominantly null findings; not supported as monotherapy or adjunctive therapy for acute episodes.

Vasudev et al. 2016 Cochrane review ²⁷ of topiramate for acute affective episodes in bipolar disorder integrated multiple small RCTs and reported insufficient evidence of benefit for mania, depression, or mixed episodes. The review recommended against routine use of topiramate for acute bipolar episodes.

FDA-approved use

FDA-Approved Uses of Topiramate

Brand	Indication	Year	Route
Topamax (immediate-release) and generic topiramate	Adjunctive therapy and monotherapy for partial-onset seizures and primary generalized tonic-clonic seizures (≥2 years); adjunctive therapy for Lennox-Gastaut syndrome (≥2 years); prophylaxis of migraine in adults	1996	Oral
Trokendi XR / Qudexy XR (extended-release)	Same epilepsy and migraine indications as Topamax in the labeled age range	2013	Oral, extended-release
Qsymia (phentermine/topiramate ER fixed-dose combination)	Chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity, as adjunct to reduced-calorie diet and increased physical activity	2012	Oral

Topamax (immediate-release topiramate, originally Janssen / Ortho-McNeil) was first approved by FDA in 1996 for adjunctive therapy of partial-onset seizures in adults ³². Subsequent approvals expanded the indication to monotherapy, to pediatric patients ≥2 years, to adjunctive Lennox-Gastaut syndrome, and (in 2004) to migraine prophylaxis in adults. Generic immediate-release topiramate has been available for many years. Extended-release products (Trokendi XR, Qudexy XR) were approved in the 2010s and offer once-daily dosing for the same indications.

Qsymia (phentermine/topiramate ER) was approved by FDA in July 2012 for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity, on the basis of the EQUIP, CONQUER, and SEQUEL trials ²¹¹⁹²⁵ ³³. The Qsymia label carries a Risk Evaluation and Mitigation Strategy (REMS) program requiring pregnancy testing and contraception counseling in women of reproductive potential due to the oral cleft teratogenic signal.

Compounded use

Compounded Topiramate (503A)

Generic immediate-release topiramate tablets and sprinkle capsules cover the majority of patient needs at low cost, and extended-release products (Trokendi XR, Qudexy XR) provide a once-daily option for adherence ³². The compounded 503A role for topiramate is therefore narrow and case-specific.

Documented patient-specific clinical reasons that may justify compounded topiramate under 503A include: (1) pediatric dose individualization at strengths not commercially available, where commercial sprinkles and tablets do not provide the prescribed dose; (2) excipient sensitivity to a component of the commercial tablet, capsule, or sprinkle formulation (dye, lactose, gluten, or other excipient); (3) preparation of an oral liquid suspension for a patient who cannot swallow capsules or tablets when commercial sprinkles are not appropriate; and (4) very rarely, custom-strength preparations for off-label indications where commercial strengths do not allow the prescribed titration ³². Cost or preference does not justify compounding under 503A ³⁵³⁴.

Transdermal and topical topiramate preparations have been explored for migraine prophylaxis in small clinical and observational settings but remain experimental; there is no FDA-approved transdermal topiramate product, and the systemic absorption profile of topical topiramate has not been adequately characterized to support claims of equivalence to oral therapy. RonanRx does not promote transdermal topiramate as an established alternative to oral therapy ³².

Most patients prescribed topiramate are well-served by the commercial generic or branded products. RonanRx compounds topiramate only when the prescriber documents that the patient cannot use a commercially available formulation for a specific clinical reason ³².

Formulations and routes

Topiramate Formulations and Routes

Form	Concentration	Description
Compounded oral suspension (503A)	Custom, typically 5-30 mg/mL	Sterile or low-bioburden oral liquid prepared under USP <795> standards for nonsterile compounding on a patient-specific prescription, typically for pediatric patients or adults unable to swallow tablets or sprinkle capsules. Container closure, excipient profile, vehicle, and concentration are documented per batch and matched to the patient's clinical profile.³⁶
Compounded oral capsules (503A)	Custom strengths outside the commercially available 15, 25, 50, 100, 150, or 200 mg increments	Patient-specific custom strengths prepared under USP <795> when the prescribed dose cannot be achieved with commercial strengths or when a documented excipient sensitivity precludes the commercial product.³⁶
Manufactured oral tablets (reference product)	25, 50, 100, 200 mg	Topamax (immediate-release) and generic topiramate are FDA-approved oral tablets for adults and pediatric patients ≥2 years.³²
Manufactured sprinkle capsules (reference product)	15, 25 mg	Topamax sprinkle capsules for pediatric use and for adults with swallowing difficulty.³²
Manufactured extended-release capsules (reference product)	25, 50, 100, 150, 200 mg	Trokendi XR (Supernus) and Qudexy XR (Upsher-Smith) once-daily extended-release capsules for the same epilepsy and migraine indications as Topamax in the labeled age range.³²
Manufactured Qsymia fixed-dose combination (reference product)	Phentermine 3.75/7.5/11.25/15 mg + topiramate ER 23/46/69/92 mg	Qsymia (Vivus) is the FDA-approved phentermine/topiramate ER combination for chronic weight management in adults, supplied as once-daily oral capsules at four fixed-dose strengths with a REMS pregnancy prevention program.³³

Routes used in published literature: oral.

Dosing

Topiramate Dosing

Route	Population	Range	Duration	Study type
Oral	Adults with partial-onset or primary generalized tonic-clonic seizures (Topamax adjunctive regimen)	Start 25-50 mg at bedtime; titrate by 25-50 mg/week to a target range of 200-400 mg/day in two divided doses. Maximum 1600 mg/day not associated with additional benefit.	Indefinite while clinically beneficial	FDA-approved labeled regimen following Faught 1996 and adjunctive program³²¹
Oral	Adults with migraine for prophylaxis	Start 25 mg/day in the evening; titrate by 25 mg/week to 100 mg/day in two divided doses (50 mg AM + 50 mg PM). Doses above 100 mg/day do not increase efficacy and worsen tolerability per MIGR-001 and MIGR-002.	Indefinite while clinically beneficial	FDA-approved labeled regimen following MIGR-001 and MIGR-002³²⁹¹⁰
Oral	Pediatric patients ≥2 years with partial-onset or primary generalized tonic-clonic seizures	Initial 1-3 mg/kg/day at bedtime, titrated by 1-3 mg/kg/week to a target of 5-9 mg/kg/day in two divided doses.	Indefinite while clinically beneficial	FDA-approved pediatric regimen³²
Oral	Adults with obesity (Qsymia labeled regimen)	Initiate at phentermine 3.75 mg / topiramate ER 23 mg once daily for 14 days, then phentermine 7.5 mg / topiramate ER 46 mg once daily. Reassess at 12 weeks: if <3% weight loss, escalate to phentermine 11.25 mg / topiramate ER 69 mg for 14 days then phentermine 15 mg / topiramate ER 92 mg once daily; if still <5% at 12 additional weeks, discontinue.	Indefinite while clinically beneficial; SEQUEL extension confirms sustained benefit at 108 weeks	FDA-approved labeled regimen following EQUIP, CONQUER, SEQUEL^33211925
Oral	Adults with alcohol use disorder (off-label)	Titrated from 25 mg/day to a target of 200-300 mg/day in two divided doses over approximately 6-8 weeks, with maintenance for 12+ weeks per the Johnson 2003 and 2007 protocols.	12+ weeks in the pivotal trials; clinical use varies	Off-label; protocol from RCTs⁸¹⁷

Doctor-prescribed and titrated. Slow titration is the primary tolerability lever for topiramate: most neurocognitive and paresthesia-related adverse events occur during dose escalation, and a 25-50 mg/week increment is the standard. For epilepsy, target maintenance is typically 200-400 mg/day in two divided doses for adults ³². For migraine prophylaxis, 100 mg/day is the labeled optimum dose with no additional benefit above this dose ⁹¹⁰. For Qsymia, the labeled regimen uses lower topiramate ER doses (23-92 mg/day) in combination with phentermine and includes a 12-week response checkpoint with discontinuation if <5% weight loss after escalation ³³.

Compounded preparations should mirror the manufactured-product dosing for the indication unless the prescriber documents a patient-specific reason for variance. Off-label use for alcohol use disorder, binge eating disorder, essential tremor, IIH, and PTSD typically targets 200-300 mg/day in two divided doses with the same slow titration.

Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.

Safety

Topiramate Safety

Safety overview

Topiramate safety is dominated by neurocognitive effects, paresthesias, metabolic acidosis, nephrolithiasis, oligohidrosis (especially in children), weight loss, and a documented teratogenic signal for oral clefts in first-trimester exposure. Neurocognitive adverse events, word-finding difficulty, psychomotor slowing, attention impairment, and verbal fluency reduction (colloquially 'dopamax'), are dose-related and disproportionately affect verbal/expressive language. Loring et al. demonstrated a relationship between topiramate plasma concentration and decrements in linguistic behavior, verbal recall, and working memory in adults with epilepsy ²³ ³². Salinsky et al. characterized EEG slowing and alertness reduction in healthy volunteers at therapeutic doses ¹⁴.

Carbonic anhydrase inhibition produces a non-anion-gap metabolic acidosis (reduced serum bicarbonate) in a substantial fraction of patients on chronic therapy ⁶. Nephrolithiasis, predominantly calcium phosphate stones, is documented across the pediatric and adult populations on chronic topiramate, reflecting carbonic anhydrase activity in renal tubules ²⁹⁶ ³². Oligohidrosis with risk of heat-related hyperthermia has been reported particularly in pediatric patients and is included in pediatric ASM pharmacovigilance signals ³¹. Other common adverse events include fatigue, dizziness, somnolence, paresthesias, anorexia, weight loss, and taste perversion (especially for carbonated beverages).

Reproductive-age women require specific counseling. First-trimester topiramate exposure is associated with an increased risk of oral clefts (cleft lip ± cleft palate) on the order of 2- to 5-fold relative to unexposed pregnancies, established by the Margulis et al. 2012 sentinel analysis ²⁴, the Hernandez-Diaz et al. 2012 comparative AED pregnancy safety analysis ²², and the Hernandez-Diaz et al. 2018 pregnancy cohort ³⁰. Topiramate at ≥200 mg/day reduces ethinyl estradiol AUC by approximately 18-30% with implications for combined oral contraceptive efficacy ³⁷ ³². The Qsymia label carries a REMS pregnancy prevention program with monthly pregnancy testing requirements ³³.

Less common but clinically important adverse events include acute myopia with secondary angle-closure glaucoma (idiosyncratic, typically within the first month), hyperammonemia and encephalopathy when combined with valproate, and rare cases of severe metabolic acidosis or suicidal ideation (class warning for antiepileptic drugs). Bipolar acute affective episode evidence is predominantly null ²⁷ and topiramate is not recommended as monotherapy or adjunctive therapy for acute bipolar episodes ³².

Contraindications

Topiramate is contraindicated in known hypersensitivity to topiramate or any excipient in the manufactured product ³². Qsymia is additionally contraindicated in pregnancy, glaucoma, hyperthyroidism, during or within 14 days of monoamine oxidase inhibitor therapy, and in known hypersensitivity to sympathomimetic amines (the phentermine component) ³³.

Topiramate is not recommended without contraception counseling and a documented contraception plan in women of reproductive potential due to the oral cleft teratogenic signal in first-trimester exposure ²⁴³⁰. Combined oral contraceptive efficacy is reduced at topiramate doses ≥200 mg/day ³⁷; patients should be advised to use a non-oral contraceptive method or add a barrier method, and to discuss alternative anticonvulsant or migraine prophylactic options if pregnancy is planned ³².

Drug interactions

Topiramate induces CYP3A4 at doses ≥200 mg/day, with the principal clinically relevant consequence being a reduction in ethinyl estradiol exposure that can lower combined oral contraceptive efficacy ³⁷. Topiramate is also a weak inhibitor of CYP2C19 and may modestly increase phenytoin levels when co-administered. Topiramate plasma concentrations are reduced by concomitant enzyme-inducing antiepileptic drugs (carbamazepine, phenytoin) and may be increased by valproate in some patients ³².

Combination with valproate has been associated with hyperammonemia and encephalopathy in adults and children. Combination with other carbonic anhydrase inhibitors (acetazolamide, zonisamide) increases the risk of metabolic acidosis and nephrolithiasis ⁶²⁹. CNS depressants (alcohol, benzodiazepines, opioids) potentiate the cognitive and sedative adverse effects of topiramate; alcohol is specifically contraindicated with Trokendi XR ³². Concomitant therapy with other agents that can cause oligohidrosis (anticholinergics, antihistamines, carbonic anhydrase inhibitors) increases the risk of heat-related illness, particularly in pediatric patients ³¹.

Adverse events

Across the pivotal epilepsy, migraine, and obesity programs, the most common adverse events with topiramate (or phentermine/topiramate ER) included paresthesias, fatigue, dizziness, somnolence, anorexia, weight loss, taste perversion, nausea, constipation, dry mouth, and cognitive/psychiatric effects (word-finding difficulty, difficulty with concentration, memory impairment) ¹⁰¹⁹²¹. Adverse-event-driven discontinuation rates were approximately 15-25% on full-dose topiramate monotherapy at 200-400 mg/day in epilepsy and migraine trials and were lower (~5-15%) on the lower-dose Qsymia regimens ¹⁴⁹.

Cognitive adverse events deserve specific mention. Loring et al. demonstrated that linguistic behavior, verbal recall, and working memory decrements correlate with topiramate plasma concentration ²³. Salinsky et al. characterized EEG slowing and alertness reduction in healthy volunteers at therapeutic doses ¹⁴. The colloquial label 'dopamax' captures the disproportionate effect on verbal fluency and word-finding that patients report. Slow titration and lower maintenance doses (e.g., 100 mg/day for migraine) substantially reduce the incidence and severity of these effects.

Less common but clinically important adverse events include nephrolithiasis (calcium phosphate stones from carbonic anhydrase inhibition) ²⁹⁶, oligohidrosis and heat-related illness particularly in pediatric patients ³¹, acute myopia with secondary angle-closure glaucoma (idiosyncratic, typically within the first month), metabolic acidosis with chronic dosing ⁶, hyperammonemia and encephalopathy in combination with valproate, and a class warning for suicidal ideation that applies to all antiepileptic drugs. Pregnancy exposure carries a 2- to 5-fold increased risk of oral clefts on the basis of pregnancy cohort and registry data ²⁴²²³⁰.

Monitoring

Monitoring Topiramate Therapy

Baseline assessment should include weight, blood pressure, heart rate, serum bicarbonate, renal function, a history focused on nephrolithiasis and ophthalmologic disease, a contraception plan in women of reproductive potential, and pregnancy testing prior to initiation (mandatory for Qsymia per REMS) ³³. Cognitive baseline (especially of verbal fluency) should be documented in patients in whom cognitive adverse events would be clinically significant.

On therapy: serum bicarbonate at 1, 3, and 12 months and as clinically indicated to detect metabolic acidosis; weight at each visit (especially in pediatric patients where excessive weight loss may be clinically problematic); periodic renal function; pregnancy testing per Qsymia REMS in women of reproductive potential; reassessment of cognitive tolerability at each titration step. Patients should be counseled to maintain hydration to reduce nephrolithiasis risk, to avoid heat exposure (particularly children), to report new visual symptoms immediately (acute myopia/angle-closure glaucoma), and to use contraception consistent with topiramate dose ³⁷ ³²³³⁶.

Special populations

Topiramate in Special Populations

Pregnancy

Topiramate is associated with an approximately 2- to 5-fold increased risk of oral clefts (cleft lip with or without cleft palate) following first-trimester exposure, established in the Margulis et al. 2012 sentinel analysis ²⁴, in the Hernandez-Diaz et al. 2012 comparative AED pregnancy safety analysis ²², and confirmed in the Hernandez-Diaz et al. 2018 pregnancy cohort study ³⁰. Topiramate was formerly classified as FDA Pregnancy Category D. Qsymia is contraindicated in pregnancy and carries a REMS pregnancy prevention program requiring monthly pregnancy testing ³³. For patients of reproductive potential who require topiramate for epilepsy or migraine prophylaxis, alternative agents should be considered preconceptionally where clinically reasonable; if topiramate is continued, the lowest effective dose should be used with documented contraception.

Lactation

Topiramate is excreted in human breast milk; reported milk-to-plasma ratios approximate unity. Limited clinical data in nursing infants have not demonstrated clear adverse effects, but plasma topiramate has been detectable in some breastfed infants. The decision to breastfeed during topiramate therapy should weigh the benefits of breastfeeding against the potential for infant exposure; pediatric monitoring for sedation and feeding adequacy is recommended ³².

Pediatric

Topiramate is FDA-approved for partial-onset and primary generalized tonic-clonic seizures and for adjunctive Lennox-Gastaut syndrome in pediatric patients ≥2 years. Migraine prophylaxis is FDA-approved in adolescents ≥12 years (Topamax) and ≥6 years (extended-release products) per their respective labels. Pediatric dosing follows weight-based escalation (1-3 mg/kg/day initiation, titrated to 5-9 mg/kg/day target). Pediatric-specific safety considerations include oligohidrosis with risk of heat-related illness ³¹, nephrolithiasis ²⁹⁶, cognitive adverse events that may affect academic performance ²³, and excessive weight loss in patients with low baseline BMI. The CHAMP trial demonstrated no separation from placebo for amitriptyline or topiramate in pediatric migraine ²⁸ ³².

Geriatric

Topiramate clearance is reduced in older adults due to age-related decline in renal function ³². Initial doses should be lower and titration slower than in younger adults, with monitoring for cognitive adverse events that may be misattributed to age-related cognitive change. Qsymia is not specifically labeled for or against geriatric use; clinical judgment is required ³³.

Renal impairment

Topiramate is approximately 70% renally excreted as unchanged drug. In patients with creatinine clearance <70 mL/min, the recommended dose is half the usual initial and maintenance dose, with slower titration. Topiramate is removed by hemodialysis; supplemental dosing may be required on dialysis days. Nephrolithiasis risk is elevated in all patients on chronic topiramate and additional caution applies in patients with known stone disease or reduced urine output ²⁹⁶ ³².

Hepatic impairment

Topiramate clearance is modestly reduced in moderate to severe hepatic impairment; cautious dosing is recommended ³². Hepatic metabolism contributes only a minor fraction of total clearance (predominantly renal elimination of unchanged drug).

Evidence quality

Topiramate Evidence Quality

Evidence supporting the manufactured topiramate products is strong across the FDA-approved indications ¹⁷. Adjunctive and monotherapy epilepsy use is supported by the Faught dose-ranging trial ¹ and the Sachdeo monotherapy and Lennox-Gastaut trials ²⁴. Migraine prophylaxis is supported by two large pivotal trials (MIGR-001 and MIGR-002) that converged on 100 mg/day as the optimum dose ¹⁰⁹ and a Cochrane review ²⁶. The Qsymia obesity program rests on EQUIP ²¹, CONQUER ¹⁹, and the two-year SEQUEL extension ²⁵, all phase III placebo-controlled with consistent effect sizes.

Off-label use is supported with varying quality. Alcohol use disorder has two well-conducted RCTs ⁸ and is the strongest off-label indication ¹⁷. Binge eating disorder ¹³, idiopathic intracranial hypertension ¹⁶, essential tremor ¹²¹⁸, and civilian PTSD ²⁰ each have single or small numbers of placebo- or comparator-controlled trials supporting efficacy. Pediatric migraine evidence is null on placebo comparison ²⁸. Bipolar acute affective episode evidence is null ²⁷.

Compounded topiramate has no separate efficacy program. Compounded preparations are an extrapolation from the commercial generic and branded products, justified case by case by patient-specific factors (excipient sensitivity, custom strength for pediatric dosing, or oral liquid for swallowing-impaired patients) ³⁴. PK and dosing should mirror the commercial product unless the prescriber documents a patient-specific reason for variance. Most patients are well-served by commercial generic immediate-release or extended-release topiramate ¹⁷.

Major studies

Major Topiramate Clinical Studies

Study	Design	Participants	Duration	Finding
Faught et al. (1996, Neurology), YD Study Group adjunctive epilepsy dose-ranging	Phase III randomized double-blind placebo-controlled dose-ranging trial of topiramate 200, 400, and 600 mg/day as adjunctive therapy in adults with refractory partial-onset seizures	181	12 weeks (after 8-week baseline)	Dose-dependent reduction in median monthly seizure frequency; 41% of topiramate-treated patients achieved ≥50% seizure reduction vs 8% on placebo. Supported the original 1996 FDA approval of Topamax for adjunctive therapy of partial-onset seizures in adults ¹.
Sachdeo et al. (1997, Epilepsia), Topiramate monotherapy for partial-onset seizures	Phase III randomized double-blind comparative dose monotherapy trial in adults with partial-onset seizures	—	Conversion-to-monotherapy design	Established topiramate monotherapy efficacy in adults with partial-onset seizures, supporting subsequent FDA approval of monotherapy use ².
Sachdeo et al. (1999, Neurology), YL Study Group Lennox-Gastaut syndrome	Phase III randomized double-blind placebo-controlled trial of topiramate as adjunctive therapy in Lennox-Gastaut syndrome	98	11 weeks	Reduction in drop-attack seizure frequency on topiramate vs placebo; supported FDA approval for adjunctive Lennox-Gastaut syndrome in patients ≥2 years ⁴.
Shank et al. (2000, Epilepsia), Preclinical pharmacology overview	Comprehensive review of preclinical pharmacology, pharmacokinetics, and mechanism of action of topiramate	—	—	Consolidated the multi-target pharmacology, sodium channel blockade, GABA-A potentiation, AMPA/kainate antagonism, L-type calcium channel blockade, carbonic anhydrase inhibition, that underpins topiramate's broad clinical spectrum ⁵.
Brandes et al. (2004, JAMA), MIGR-002 migraine prophylaxis	Phase III randomized double-blind placebo-controlled trial of topiramate 50, 100, 200 mg/day for migraine prophylaxis in adults	483	26 weeks	Mean reduction in monthly migraine days of 1.4, 2.1, and 2.4 on 50, 100, and 200 mg/day vs 0.8 on placebo. Established 100 mg/day as the optimum dose with no further benefit and worse tolerability at 200 mg/day. Supported 2004 FDA approval for migraine prophylaxis in adults ⁹.
Silberstein et al. (2004, Archives of Neurology), MIGR-001 migraine prophylaxis	Phase III randomized double-blind placebo-controlled trial of topiramate 50, 100, 200 mg/day for migraine prophylaxis in adults	487	26 weeks	Parallel MIGR program trial converging on the same 100 mg/day optimum dose with significant reduction in monthly migraine days vs placebo. Together with MIGR-002 supported 2004 FDA migraine prophylaxis approval ¹⁰.
Wilding et al. (2004, Int J Obes Relat Metab Disord), Long-term obesity monotherapy	Randomized double-blind placebo-controlled trial of topiramate monotherapy at escalating doses up to 384 mg/day in obese adults	—	60 weeks	Dose-dependent weight reduction; high-dose monotherapy poorly tolerated due to neurocognitive and paresthesia-related adverse events, motivating the lower-dose combination with phentermine ¹¹.
Ondo et al. (2006, Neurology), Essential tremor RCT	Phase III randomized double-blind placebo-controlled trial of topiramate titrated to 400 mg/day in adults with essential tremor	208	24 weeks	Significant reduction in Fahn-Tolosa-Marin tremor rating scale on topiramate vs placebo; discontinuation rate ~32% in the topiramate arm due to adverse events ¹².
McElroy et al. (2007, Biological Psychiatry), Binge eating disorder	Randomized double-blind placebo-controlled trial of topiramate (mean ~212 mg/day) in adults with binge eating disorder and obesity	394	21 weeks	Significant reductions in binge episode frequency, BMI, and Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating vs placebo ¹³. Establishes well-studied off-label use; not FDA-approved for this indication.
Salinsky et al. (2007, Epilepsy & Behavior), Topiramate EEG and alertness	Healthy-volunteer study of topiramate effects on EEG and alertness at therapeutic doses	—	—	Documented EEG slowing and alertness reduction at therapeutic plasma concentrations; characterized topiramate's distinct neurotoxicity profile relative to other antiepileptic drugs ¹⁴.
Diener et al. (2007, Cephalalgia), Chronic migraine RCT	Randomized double-blind placebo-controlled trial of topiramate 100 mg/day in adults with chronic migraine	—	16 weeks	Significant reduction in monthly headache days on topiramate vs placebo; supports off-label use in chronic migraine in addition to the labeled episodic migraine indication ¹⁵.
Çelebisoy et al. (2007, Acta Neurologica Scandinavica), IIH topiramate vs acetazolamide	Open-label comparison of topiramate vs acetazolamide in adults with idiopathic intracranial hypertension	—	12 months	Comparable improvements in visual fields, headache severity, and papilledema between topiramate and acetazolamide; topiramate's carbonic anhydrase inhibition is the proposed mechanistic basis ¹⁶.
Johnson et al. (2003, Lancet), Topiramate for alcohol dependence (initial RCT)	Phase II randomized double-blind placebo-controlled trial of topiramate titrated to 300 mg/day in adults with alcohol dependence	150	12 weeks	Significant reductions in drinks per day, drinks per drinking day, percent days heavy drinking, and gamma-glutamyltransferase on topiramate vs placebo. Established topiramate as a candidate pharmacotherapy for alcohol use disorder ⁸.
Johnson et al. (2007, JAMA), Topiramate for alcohol dependence (multi-site RCT)	Phase III randomized double-blind placebo-controlled multi-site trial of topiramate titrated to 300 mg/day in adults with alcohol dependence	371	14 weeks	Replication of the 2003 result with a 3.4-percentage-point reduction in percent heavy drinking days vs placebo; established topiramate as an evidence-supported (though off-label) option for alcohol use disorder ¹⁷.
Connor et al. (2008, Clinical Neuropharmacology), Essential tremor crossover trials	Pooled double-blind placebo-controlled crossover trials of topiramate in adults with essential tremor	—	—	Significant reduction in tremor severity on topiramate vs placebo; corroborates the Ondo 2006 finding with crossover-design evidence ¹⁸.
Gadde et al. (2011, Lancet), CONQUER phentermine/topiramate ER	Phase III randomized double-blind placebo-controlled trial of low- and full-dose phentermine/topiramate ER in overweight and obese adults with weight-related comorbidities	2487	56 weeks	Mean weight reductions of 7.8% and 9.8% with mid-dose (7.5/46) and full-dose (15/92) phentermine/topiramate ER vs 1.2% on placebo; ≥5% weight loss in 62% and 70% vs 21% on placebo ¹⁹. Supported the 2012 FDA approval of Qsymia.
Yeh et al. (2011, CNS Neuroscience & Therapeutics), Civilian PTSD RCT	Double-blind randomized placebo-controlled trial of topiramate titrated to 200 mg/day in adults with civilian PTSD	—	12 weeks	Significant improvement on the Clinician-Administered PTSD Scale (CAPS) with topiramate vs placebo; supports off-label use in civilian PTSD; topiramate is not FDA-approved for PTSD ²⁰.
Allison et al. (2012, Obesity), EQUIP phentermine/topiramate ER in severe obesity	Phase III randomized double-blind placebo-controlled trial of low-dose and full-dose phentermine/topiramate ER in adults with severe obesity (BMI ≥35)	1267	56 weeks	Mean weight reductions of 5.1% and 10.9% with low-dose and full-dose phentermine/topiramate ER vs 1.6% on placebo; ≥10% weight loss in 7%, 47%, and 7% respectively ²¹. Co-pivotal with CONQUER for Qsymia approval.
Garvey et al. (2012, Am J Clin Nutr), SEQUEL two-year phentermine/topiramate ER extension	Phase III randomized placebo-controlled 52-week extension of CONQUER (total 108 weeks of treatment) with mid- and full-dose phentermine/topiramate ER	676	108 weeks total	Sustained weight loss of 9.3% and 10.5% on mid- and full-dose vs 1.8% on placebo at 108 weeks; sustained improvement in metabolic parameters (HbA1c, lipids, blood pressure); supported long-term use of Qsymia ²⁵.
Loring et al. (2012, Epilepsy & Behavior), Topiramate plasma concentration and language	Observational analysis of the relationship between topiramate plasma concentration and linguistic behavior, verbal recall, and working memory in adults with epilepsy	—	—	Concentration-dependent decrements in linguistic behavior, verbal recall, and working memory; provides the mechanistic substrate for the colloquial 'dopamax' description of topiramate's effect on word-finding and verbal fluency ²³.
Margulis et al. (2012, AJOG), Topiramate pregnancy and oral clefts	Population-based pregnancy cohort study using insurance claims data to assess topiramate exposure and oral cleft risk	—	—	Increased risk of oral clefts among infants of women with first-trimester topiramate exposure relative to unexposed comparators; sentinel analysis prompting label change and Qsymia REMS ²⁴.
Hernandez-Diaz et al. (2012, Neurology), Comparative AED pregnancy safety	Comparative safety analysis of antiepileptic drugs during pregnancy using a multi-source pregnancy registry	—	—	Confirmed elevated oral cleft risk with first-trimester topiramate exposure in the context of broader AED comparative safety; informed contemporaneous regulatory action ²².
Linde et al. (2013, Cochrane Database of Systematic Reviews), Topiramate migraine prophylaxis review	Systematic review and meta-analysis of randomized placebo-controlled trials of topiramate for episodic migraine prophylaxis in adults	—	—	Topiramate 100 mg/day reduces mean monthly migraine days by ~1 day relative to placebo with consistent effect sizes across trials; 200 mg/day does not increase efficacy and worsens tolerability ²⁶.
Vasudev et al. (2016, Cochrane), Topiramate for acute affective episodes in bipolar disorder	Cochrane systematic review and meta-analysis of topiramate for acute mania, depression, and mixed episodes in bipolar disorder	—	—	Predominantly null findings; insufficient evidence to support topiramate as monotherapy or adjunctive therapy for acute bipolar affective episodes ²⁷.
Powers et al. (2017, NEJM), CHAMP pediatric migraine	Phase III randomized double-blind placebo-controlled trial of amitriptyline 1 mg/kg/day, topiramate 2 mg/kg/day, or placebo in children and adolescents 8-17 years with migraine	361	24 weeks	Neither active arm separated from placebo on the primary endpoint of ≥50% reduction in headache days; the trial was stopped early for futility. Tempered enthusiasm for routine prophylactic pharmacotherapy in pediatric migraine ²⁸.
Hernandez-Diaz et al. (2018, Neurology), Topiramate pregnancy oral clefts cohort	Large pregnancy cohort study using nationwide insurance claims to assess oral cleft risk with first-trimester topiramate exposure	—	—	Confirmed approximately 2- to 3-fold increased risk of oral clefts with first-trimester topiramate exposure vs unexposed comparators across the migraine and epilepsy indications ³⁰.
Daudon et al. (2018, Drugs), Drug-induced kidney stones review	Comprehensive review of drug-induced kidney stones and crystalline nephropathy, including detailed coverage of topiramate-associated calcium phosphate stones	—	—	Topiramate-associated nephrolithiasis is predominantly calcium phosphate driven by carbonic anhydrase inhibition with reduced citrate excretion and alkaline urine; management includes hydration, dietary modification, and consideration of dose reduction or alternative therapy in recurrent stone formers ²⁹.
Kossoff et al. (2002, Epilepsia), Kidney stones, CA inhibitors, ketogenic diet	Clinical analysis of nephrolithiasis risk in pediatric patients on carbonic anhydrase inhibitors (including topiramate) and the ketogenic diet	—	—	Documented increased nephrolithiasis incidence in pediatric patients on topiramate, particularly in combination with the ketogenic diet; established nephrolithiasis as a class effect of CA inhibitors ⁶.
Doose et al. (1997, Epilepsia), Topiramate and oral contraceptive PK in epilepsy	Pharmacokinetic study of topiramate's effect on the PK of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy	—	—	Topiramate at higher doses reduces ethinyl estradiol AUC by approximately 18-30%, with implications for combined oral contraceptive efficacy ³. Established the basis for contraception counseling on topiramate.
Doose et al. (2003, Epilepsia), Topiramate or carbamazepine OC PK in healthy obese and non-obese	Pharmacokinetic study comparing topiramate and carbamazepine on PK of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects	—	—	Extended the 1997 result into a healthy-volunteer population; confirmed dose-dependent reduction in ethinyl estradiol exposure on topiramate ⁷.
Franco et al. (2021, Epilepsy & Behavior), Pediatric ASM AE Italian reporting analysis	Analysis of pediatric adverse reactions to antiseizure medications in the Italian spontaneous reporting system 2001-2019	—	—	Catalogued pediatric-specific adverse events to topiramate including oligohidrosis, metabolic acidosis, nephrolithiasis, and cognitive effects; informs pediatric monitoring practice ³¹.

Mechanism detail

Detailed Mechanism of Topiramate

Sodium-channel modulation by topiramate is state-dependent and frequency-dependent, similar in profile to phenytoin and carbamazepine but with distinct binding kinetics. GABA-A potentiation occurs at a site distinct from the benzodiazepine and barbiturate sites, supporting an inhibitory neurotransmission boost that is additive with established GABAergic anticonvulsants. AMPA/kainate antagonism is selective relative to NMDA receptors and contributes to dampening of excitatory neurotransmission, which is mechanistically attractive in both seizure and migraine contexts. L-type voltage-gated calcium-channel blockade adds a further layer of excitability modulation. Carbonic anhydrase inhibition affects the type II and type IV isoforms preferentially over type I ⁵.

Pharmacological coverage of multiple targets is why topiramate is described as a 'broad-spectrum' anticonvulsant: it is effective in partial-onset seizures, primary generalized tonic-clonic seizures, and Lennox-Gastaut syndrome ¹²⁴. In migraine, the same pharmacology supports a prophylactic effect demonstrated in MIGR-001 ¹⁰ and MIGR-002 ⁹. In obesity, the appetite-suppressant and weight-reducing effects are leveraged in the Qsymia combination with phentermine ¹⁹²¹²⁵. In alcohol use disorder, dampened glutamatergic neurotransmission and enhanced GABAergic tone are thought to attenuate craving and reduce heavy drinking ⁸¹⁷.

Carbonic anhydrase inhibition has direct safety consequences. Reduced renal bicarbonate reabsorption produces a mild non-anion-gap metabolic acidosis in a substantial fraction of patients on chronic therapy ⁶. The same enzyme inhibition in renal tubules favors calcium phosphate stone formation, contributing to a documented increase in nephrolithiasis ²⁹. Reduced sweating (oligohidrosis), particularly described in pediatric patients, also reflects carbonic anhydrase activity in eccrine sweat glands ³¹.

Pharmacology

Topiramate Pharmacokinetics & Pharmacodynamics

Pharmacokinetics

Topiramate is rapidly absorbed after oral administration with bioavailability of approximately 80% and a time to maximum plasma concentration of 1-4 hours for immediate-release tablets and 5-15 hours for extended-release capsules. It is approximately 15-41% protein-bound. Steady-state is reached after approximately 4-8 days of dosing in patients with normal renal function. The elimination half-life is approximately 21 hours, supporting twice-daily immediate-release or once-daily extended-release dosing ⁵.

Approximately 70% of topiramate is eliminated unchanged in the urine; the remainder is metabolized by hydrolysis, hydroxylation, and glucuronidation. Renal clearance is the principal elimination pathway and dose reduction is required in moderate to severe renal impairment. Topiramate is removed by hemodialysis with supplemental dosing required on dialysis days ³².

Topiramate is a weak inducer of CYP3A4 at doses ≥200 mg/day, reducing ethinyl estradiol exposure by approximately 18-30% ³⁷. It is a weak inhibitor of CYP2C19. Concomitant enzyme-inducing antiepileptic drugs (carbamazepine, phenytoin) reduce topiramate plasma concentrations by approximately 40-50% via induction of topiramate's minor metabolic pathways.

Pharmacodynamics

Pharmacodynamic effects reflect topiramate's multi-target pharmacology and are reliably observed across the clinical indications. Anticonvulsant effects (reduction in seizure frequency for partial-onset, primary generalized tonic-clonic, and Lennox-Gastaut drop-attack seizures) dominate the labeled epilepsy indications ¹⁴. Migraine prophylactic effects (reduction in monthly migraine days) are observed at 100 mg/day with no additional benefit at higher doses ⁹¹⁰. Weight reduction is dose-related and is the basis for the Qsymia obesity combination ¹⁹²¹²⁵.

Secondary pharmacodynamic effects include reduction in serum bicarbonate (mild non-anion-gap metabolic acidosis) from carbonic anhydrase inhibition ⁶, reduction in urinary citrate excretion contributing to calcium phosphate nephrolithiasis ²⁹, reduction in sweat output (oligohidrosis, particularly in pediatric patients) ³¹, and dose-related decrements in verbal fluency, word-finding, and working memory ²³¹⁴.

Comparative formulations

Comparing Topiramate Formulations

Manufactured topiramate is available as immediate-release tablets (25, 50, 100, 200 mg; Topamax and generics), sprinkle capsules (15, 25 mg; Topamax), and extended-release capsules (25, 50, 100, 150, 200 mg; Trokendi XR and Qudexy XR) ³². Qsymia is supplied as fixed-dose phentermine/topiramate ER capsules at 3.75/23, 7.5/46, 11.25/69, and 15/92 mg with a REMS pregnancy prevention program ³³.

Compounded topiramate preparations are oral capsules, oral suspensions, or other patient-specific oral forms prepared under USP <795> ³⁶. They are not bioequivalent to the commercial products; clinicians should anticipate that local PK and tolerability may differ from manufactured-product published data and re-evaluate titration when switching from a commercial product to a compounded preparation.

Storage

Topiramate Storage and Handling

Manufactured topiramate tablets, sprinkle capsules, and extended-release capsules are stored at room temperature (20-25°C) in the original container; protection from moisture is recommended ³². Qsymia is stored at room temperature with the same conditions ³³. Compounded oral suspensions and capsules are stored per the pharmacy's stability data and beyond-use date assignment under USP <795>; refrigerated storage is typical for oral liquids to extend stability ³⁶.

RonanRx operations

Topiramate Compounding & Operations

503A compounding

Compounded topiramate is prepared under 503A on patient-specific prescriptions in state-licensed compounding pharmacies. RonanRx prepares oral capsules, oral suspensions, and other oral dosage forms per USP General Chapter <795>, the official compendial standard for nonsterile pharmaceutical compounding, with documented active ingredient sourcing, gravimetric verification, and beyond-use date assignment per the pharmacy's quality-management system ³⁵³⁶.

Ingredient identity verification, beyond-use dating, and stability assessment follow USP <795> requirements ³⁵. Each compounded batch is documented per state board of pharmacy retention rules with full traceability from API lot through dispensing. Generic topiramate is widely available, so the compounded role is narrow; RonanRx does not fill prescriptions that read as routine substitution of compounded for commercial topiramate without documented clinical rationale ³⁴.

Pharmacist review

Each prescription for compounded topiramate undergoes pharmacist review prior to dispensing. The review confirms: a documented patient-specific clinical reason that the commercial Topamax, generic immediate-release, extended-release, sprinkle, or Qsymia product is not appropriate (excipient sensitivity, custom strength for pediatric dosing, oral liquid for swallowing-impaired patients); absence of contraindications (hypersensitivity to topiramate, pregnancy without REMS-equivalent counseling for weight-management use, untreated narrow-angle glaucoma); appropriate concomitant medication review including oral contraception counseling at topiramate doses ≥200 mg/day ³⁷ and consideration of CNS depressant and carbonic anhydrase inhibitor interactions; and a prescribed regimen consistent with the labeled or evidence-based titration unless the prescriber documents a patient-specific reason ³²³³.

RonanRx does not fill prescriptions that read as routine substitution of compounded for commercial topiramate, consistent with FDA guidance on compounded copies of commercially available drugs ³⁴ ³². Pregnancy testing and a documented contraception plan are reviewed for every patient of reproductive potential ²⁴³⁰.

Quality and traceability

Active pharmaceutical ingredients are sourced from FDA-registered facilities with documented certificates of analysis. Each batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, identity verification test result, and dispensing pharmacist of record. Finished product lot records are retained per state board of pharmacy retention requirements.

Cold chain

Compounded topiramate capsules are stored and shipped at room temperature ³². Compounded oral suspensions are typically refrigerated to extend stability and are shipped with appropriate cold-chain controls when assigned a refrigerated beyond-use date. Manufactured topiramate is stored at room temperature with protection from moisture per labeling.

FAQ

Frequently Asked Questions About Topiramate

Is compounded topiramate the same as Topamax or generic topiramate?

No. Topamax and the immediate-release generics, Trokendi XR, Qudexy XR, and Qsymia are FDA-approved manufactured topiramate products ³²³³. Compounded topiramate is pharmacy-prepared on a patient-specific prescription and is not bioequivalent to the manufactured products. Compounded drugs are not FDA-approved ³⁵.

When is a compounded version appropriate?

Per FDA guidance, a compounded version of an FDA-approved drug is generally restricted unless the prescriber documents a patient-specific clinical need that the manufactured product cannot meet, for example, excipient sensitivity, a custom strength for pediatric dosing outside the commercial increments, or an oral liquid suspension for a patient unable to swallow capsules or tablets ³⁴. Cost or preference does not qualify under section 503A.

What is topiramate FDA-approved for?

Topiramate (Topamax and generics) is FDA-approved for adjunctive therapy and monotherapy of partial-onset and primary generalized tonic-clonic seizures (ages ≥2 years), adjunctive therapy of Lennox-Gastaut syndrome (≥2 years), and migraine prophylaxis in adults ³². Qsymia (phentermine/topiramate ER) is FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 plus a weight-related comorbidity ³³.

What are the most common side effects?

Paresthesias (tingling in hands and feet), fatigue, dizziness, somnolence, decreased appetite, weight loss, taste perversion (especially for carbonated beverages), and cognitive/word-finding difficulty colloquially called 'dopamax'. Most are dose-related and improve with slow titration or dose reduction ⁶³¹. Less common but important: kidney stones, mild metabolic acidosis, reduced sweating in children with risk of heat-related illness, and acute myopia with angle-closure glaucoma in the first month ²³¹⁴²⁹.

Why is topiramate a concern in pregnancy?

First-trimester topiramate exposure increases the risk of oral clefts (cleft lip with or without cleft palate) approximately 2- to 5-fold relative to unexposed pregnancies ²⁴³⁰. Qsymia is contraindicated in pregnancy and requires monthly pregnancy testing under a REMS program ³³. For epilepsy or migraine prophylaxis in women of reproductive potential, contraception counseling is essential and alternative agents should be considered preconceptionally where reasonable.

Does topiramate make birth control pills less effective?

Yes, at doses ≥200 mg/day topiramate reduces ethinyl estradiol exposure by approximately 18-30%, which can lower combined oral contraceptive efficacy ³⁷. Patients on these doses should use a non-oral contraceptive method or add a barrier method. At lower doses (e.g., 100 mg/day for migraine prophylaxis), the effect is smaller but contraception counseling is still appropriate.

Does RonanRx sell compounded topiramate directly to patients?

No. Compounded topiramate requires a patient-specific prescription written by a licensed doctor for an identified patient with a documented clinical reason that a commercial product is not appropriate, plus pharmacist review before dispensing ³⁴. RonanRx is not a direct-to-consumer storefront ³⁵.

Clinician resource

Download the Topiramate Clinical Monograph (PDF)

The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.

Download information packet ↓

References

[faught1996] Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, Karim RM. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group.. Neurology. 1996. PMID 8649570. (accessed 2026-05-11)
[sachdeo1997] Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures.. Epilepsia. 1997. PMID 9070591. (accessed 2026-05-11)
[doose1997] Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.. Epilepsia. 1997. PMID 9070594. (accessed 2026-05-11)
[sachdeo1999] Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.. Neurology. 1999. PMID 10371538. (accessed 2026-05-11)
[shank2000] Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action.. Epilepsia. 2000. PMID 10768292. (accessed 2026-05-11)
[kossoff2002] Kossoff EH, Pyzik PL, Furth SL, Hladky HD, Freeman JM, Vining EP. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet.. Epilepsia. 2002. PMID 12366731. (accessed 2026-05-11)
[doose2003] Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.. Epilepsia. 2003. PMID 12681003. (accessed 2026-05-11)
[johnson2003] Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial.. Lancet. 2003. PMID 12767733. (accessed 2026-05-11)
[brandes2004] Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwabe S, Jacobs D; MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial.. JAMA. 2004. PMID 14982912. (accessed 2026-05-11)
[silberstein2004] Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial.. Archives of Neurology. 2004. PMID 15096395. (accessed 2026-05-11)
[wilding2004] Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.. International Journal of Obesity and Related Metabolic Disorders. 2004. PMID 15486569. (accessed 2026-05-11)
[ondo2006] Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, Koller WC, Schwarzman L, Wu SC, Hulihan JF; Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial.. Neurology. 2006. PMID 16436648. (accessed 2026-05-11)
[mcelroy2007] McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR; Topiramate Binge Eating Disorder Research Group. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study.. Biological Psychiatry. 2007. PMID 17258690. (accessed 2026-05-11)
[salinsky2007] Salinsky MC, Storzbach D, Spencer DC, Oken BS, Landry T, Dodrill CB. Topiramate effects on the EEG and alertness in healthy volunteers: a different profile of antiepileptic drug neurotoxicity.. Epilepsy & Behavior. 2007. PMID 17337249. (accessed 2026-05-11)
[diener2007] Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ; TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.. Cephalalgia. 2007. PMID 17441971. (accessed 2026-05-11)
[celebisoy2007] Çelebisoy N, Gökçay F, Şirin H, Akyürekli O. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study.. Acta Neurologica Scandinavica. 2007. PMID 17922725. (accessed 2026-05-11)
[johnson2007] Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial.. JAMA. 2007. PMID 17925516. (accessed 2026-05-11)
[connor2008] Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials.. Clinical Neuropharmacology. 2008. PMID 18382182. (accessed 2026-05-11)
[gadde2011] Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.. Lancet. 2011. PMID 21481449. (accessed 2026-05-11)
[yeh2011] Yeh MS, Mari JJ, Costa MC, Andreoli SB, Bressan RA, Mello MF. A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD.. CNS Neuroscience & Therapeutics. 2011. PMID 21554564. (accessed 2026-05-11)
[allison2012] Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).. Obesity. 2012. PMID 22051941. (accessed 2026-05-11)
[hernandezdiaz2012] Hernández-Díaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, Holmes LB; North American AED Pregnancy Registry; North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy.. Neurology. 2012. PMID 22551726. (accessed 2026-05-11)
[loring2012] Loring DW, Williamson DJ, Meador KJ, Wiegand F, Hulihan J. The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory.. Epilepsy & Behavior. 2012. PMID 22658432. (accessed 2026-05-11)
[margulis2012] Margulis AV, Mitchell AA, Gilboa SM, Werler MM, Mittleman MA, Glynn RJ, Hernandez-Diaz S; National Birth Defects Prevention Study. Use of topiramate in pregnancy and risk of oral clefts.. American Journal of Obstetrics and Gynecology. 2012. PMID 22917484. (accessed 2026-05-11)
[garvey2012] Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.. American Journal of Clinical Nutrition. 2012. PMID 22158731. (accessed 2026-05-11)
[linde2013] Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults.. Cochrane Database of Systematic Reviews. 2013. PMID 23797676. (accessed 2026-05-11)
[vasudev2016] Pigott K, Galizia I, Vasudev K, Watson S, Geddes J, Young AH. Topiramate for acute affective episodes in bipolar disorder in adults.. Cochrane Database of Systematic Reviews. 2016. PMID 27591453. (accessed 2026-05-11)
[powers2017] Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD; CHAMP Investigators. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine.. New England Journal of Medicine. 2017. PMID 27788026. (accessed 2026-05-11)
[daudon2018] Daudon M, Frochot V, Bazin D, Jungers P. Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.. Drugs. 2018. PMID 29264783. (accessed 2026-05-11)
[hernandezdiaz2018] Hernández-Díaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, Pennell PB, Bateman BT, Patorno E. Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study.. Neurology. 2018. PMID 29282333. (accessed 2026-05-11)
[franco2021] Franco V, Barbieri MA, Cutroneo PM, Arena I, Cicala G, Marchione P, Spina E, Perucca E. Pediatric adverse reactions to antiseizure medications - An analysis of data from the Italian spontaneous reporting system (2001-2019).. Epilepsy & Behavior. 2021. PMID 33946010. (accessed 2026-05-11)
[fda_label_topamax] Janssen Pharmaceuticals, Inc. (via DailyMed / U.S. National Library of Medicine). Topamax (topiramate) tablets and sprinkle capsules — Prescribing Information. DailyMed. 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21628112-0c47-11df-95b3-498d55d89593 (accessed 2026-05-11)
[fda_label_qsymia] Vivus LLC (via DailyMed / U.S. National Library of Medicine). Qsymia (phentermine and topiramate) capsule, extended release — Prescribing Information. DailyMed. 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40dd5602-53da-45ac-bb4b-15789aba40f9 (accessed 2026-05-11)
[fda_essentially_a_copy] U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry. FDA Guidance for Industry. 2018. https://www.fda.gov/media/98973/download (accessed 2026-05-11)
[fda503a] U.S. Food and Drug Administration. Compounding Laws and Policies — Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA Drug Compounding. 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies (accessed 2026-05-11)
[usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)

How to access

How to Access Topiramate

Compounded Topiramate is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.

For doctors

Offer this medication.

A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.

Offer this medication →

Patient with a doctor

Receive your prescription.

If your doctor has already prescribed Topiramate, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.

Patient without a doctor

Find a partner clinic.

RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Topiramate.

Find a partner clinic →